Who
Russell J. Cox
Director
Company insider
Files Form 4 as: Director, Gossamer Bio; Director, Spyre Therapeutics; Chief Executive Officer, Immunic; EVP & COO, Jazz Pharmaceuticals.
In numbers
- Trades disclosed
- 95
- Buys
- 2
- Sells
- 13
- Bought
- $185K
- Sold
- $3.7M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 10 Mar 2011
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 6 Jun 2024filed 6 Jun 2024 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 22 Jun 2023filed 30 Jun 2023 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,950,000 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 9 Jun 2022filed 15 Jul 2022 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,000 at $0.00 | filing |
| 9 Jun 2021filed 10 Jun 2021 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 8 Jun 2021filed 9 Jun 2021 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 17 Jun 2020filed 18 Jun 2020 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 8 Jun 2020filed 10 Jun 2020 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,100 at $0.00 | filing |
| 10 Jun 2019filed 11 Jun 2019 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 7 Jun 2019filed 7 Jun 2019 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,400 at $0.00 | filing |
| 12 Feb 2019filed 12 Feb 2019 | GOSS Gossamer BioBiotechnology | SEC FORM 4 Bought | $115K7,200 at $16.00 | filing |
| 11 Jan 2019filed 14 Jan 2019 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,588,832 at $0.00 | filing |
| 11 Jan 2019filed 14 Jan 2019 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,854,376 at $0.00 | filing |
| 7 Jun 2018filed 8 Jun 2018 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,400 at $0.00 | filing |
News
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026Jazz Pharmaceuticals gets Cramer's vote of confidenceJAZZ · aol.com · 14 Oct 2026Chardan Capital Begins Coverage on Gossamer Bio (NASDAQ:GOSS)GOSS · themarketsdaily.com · 13 Oct 2026Critical Analysis: vTv Therapeutics (NASDAQ:VTVT) and Jazz Pharmaceuticals (NASDAQ:JAZZ)JAZZ · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Russell J. Cox; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.